Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | IDH2 | P48735 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18309765 | 0.85 | SMN1; SMN2 (0.39) | CFTRKCNH2SMN1; SMN2IDH1IDH2 | |
| SCHEMBL17031844 | 0.85 | CFTR (0.34) | CFTRKDM4EPTGESGRM5 | |
| SCHEMBL18313969 | 0.84 | GRM5 (0.43) | CFTRKCNH2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL17031823 | 0.76 | PDE2A (0.43) | KCNH2PTGES | |
| SCHEMBL17031824 | 0.76 | USP28 (0.42) | ALDH1A1 | |
| SCHEMBL17031833 | 0.75 | MEN1 (0.43) | SMN1; SMN2ALDH1A1PTGES | |
| SCHEMBL19822692 | 0.75 | MPL (0.35) | CFTRKCNH2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL19091156 | 0.75 | KDM4E (0.34) | SMN1; SMN2IDH1IDH2KDM4EALDH1A1 | |
| SCHEMBL17031827 | 0.74 | HSP90AA1 (0.51) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL17032674 | 0.74 | CNR2 (0.47) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190085005-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| US-9828396-B2 | Alkyne compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190085005-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, C1QBP | CFTR 2055/4885KCNH2 4301/4885SMN1; SMN2 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.